Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sanofi-Aventis and Bristol-Myers Squibb have announced that the US Court of Appeals for the federal circuit has upheld the June 19, 2007 decision by the US District Court of New York holding the US patent covering clopidogrel bisulphate, the active ingredient in Plavix, valid and enforceable.
Subscribe to our email newsletter
As a result of this ruling, the patent protection for this product is maintained in the US until November 2011.
Sanofi-Aventis and Bristol-Myers Squibb are seeking damages from Apotex, in reparation of harm caused by that company’s marketing and sale of an infringing generic version of Plavix in 2006.